Printer Friendly

'IDEAL' DRUGS FOR CARDIOVASCULAR DISEASES TO BE MODELED IN RESEARCH PROGRAM BY DECISION RESOURCES

 WALTHAM, April 12 /PRNewswire/ -- In the U.S., cardiovascular disease accounts for almost 45 percent of all deaths; more than 70 million Americans have one or more forms of heart or blood vessel disease, and over 6 million have a history of heart attack or angina pectoris. The worldwide market for cardiovascular drugs in 1993 is $38 billion, according to Decision Resources' estimates, and in the U.S., $10 billion. Decision Resources' newly launched Cardium program will assess the pharmaceuticals now used to treat cardiovascular disease, and project the clinical and commercial prospects of those drugs still in the research pipeline.
 Planned Cardium topics include congestive heart failure, hyperlipidemia, myocardial infarction, hypertension and pharmacoeconomics, cardiovascular disease in diabetic patients, atherosclerosis, angina pectoris, arrhythmias, and peripheral vascular disease. For each condition, a qualitative profile of the ideal drug will be developed, based on physicians' perceptions of needs that are unmet by current therapies. Decision Resources' analyses draw on the expert opinions of leading medical authorities in the U.S., England, France, Germany, Italy, Spain, and Japan.
 As part of the series, Decision Resources is also introducing an innovative pharmacoeconomic assessment that will gauge, simply and objectively, the balance point between clinical needs and societal costs. This unique analysis, which will be included as part of all Cardium studies, is based on the concept of the idealized drug. The pricing of such an ideal agent, under market-driven economic conditions, will be used as a means of benchmarking the cost-containment pressures that prevail worldwide.
 Decision Resources, Inc., identifies and evaluates the business implications of technological change. The Life Sciences division of Decision Resources independently analyzes drugs for central nervous system disorders, infectious diseases, and cancer, as well as the markets for those drugs. Other services of the Life Sciences division address issues in biotechnology, medical devices and diagnostics, other pharmaceuticals, and health care delivery. Besides its Life Sciences services, Decision Resources also serves the telecommunications, information systems, chemicals, food, and environmental industries.
 -0- 4/12/93
 /CONTACT: Maryann Benedict, 617-487-3721 Cardium Research Program Mgr: Ellen Williams, 617-487-3799/


CO: Decision Resources ST: Massachusetts IN: MTC SU: PDT

TM -- NE006 -- 4827 04/12/93 14:10 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 12, 1993
Words:362
Previous Article:'INDECENT PROPOSAL' GROSSES $18.3 MILLION TO BECOME NO. 1 FILM DURING FIRST WEEKEND IN RELEASE TAKING 35 PERCENT OF OVERALL BOX OFFICE
Next Article:SMITHKLINE BEECHAM CLINICAL LABORATORIES BREAKS GROUND FOR NEW FACILITY IN FARMINGTON HILLS
Topics:


Related Articles
TEXAS BIOTECHNOLOGY SIGNS DEFINITIVE AGREEMENT TO ACQUIRE IMMUNOPHARMACEUTICS
TEXAS BIOTECHNOLOGY RECEIVES FIRST PATENT ISSUED FOR NEW CLASS OF CARDIOVASCULAR DRUGS
AnVil and Genomics Collaborative Form Strategic Alliance to Market Clinical Information and Analysis; Industry leaders to advance new predictive and...
DecisionBase 8 Reveals the Commercial Opportunity for Drugs in Development in 35 High-Profile Disease States; Drug Markets for Diabetic Retinopathy...
New Treatment Guidelines for Long-Neglected Peripheral Arterial Disease Will Drive the Drug Market; The Gold-Standard Method for Diagnosis of the...
Johnson & Johnson's Proposed Purchase of Guidant Could Spur More Consolidation in the Cardiovascular Device Market, According to a New Report From...
DecisionBase 9 Reveals the Commercial Opportunity for Drugs in Development in 35 High-Profile Disease States; New Feature Allows Pharma Business...
Report Series Uncovers the Commercial Outlook for Currently Marketed Drugs and Drugs in Research and Development.
SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano).

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters